🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Joleen M. Hubbard

Allina Health

ORCID: 0000-0001-8250-4920

Also affiliated with Mayo Clinic in Arizona

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.

3 citations

Tyler Zemla, Joleen M. Hubbard, John H. Strickler, Olumide B. Gbolahan, L. R. Wilson +6 more

10 citations

Nathan R. Foster, Amit Mahipal, Thomas Byrne, Joleen M. Hubbard, Alvin Silva +4 more

0 citations

Douglas W. Mahoney, Kelli N. Burger, Patrick H. Foote, Karen A. Doering, William R. Taylor +8 more

7 citations

Joleen M. Hubbard, Paul J. Novotny, Megan E. Branda, Daniel S. Sargent, Roscoe F. Morton +8 more

3 citations

Cody Eslinger, Kenneth Lee, Lama F. Farchoukh, Daniel Walden, Oluwadunni Emiloju +13 more